Aceragen to pull out of Nasdaq and liquidate assets, ending tumultuous journey for Idera Pharma
Aceragen is set to cease its Nasdaq listing, the next step for the beleaguered company whose assets are slated to be liquidated. The company has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
